Evolus, Inc. $EOLS Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. grew its stake in Evolus, Inc. (NASDAQ:EOLS) by 121.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 598,145 shares of the company’s stock after acquiring an additional 327,926 shares during the quarter. Assenagon Asset Management S.A. owned about 0.92% of Evolus worth $2,458,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Larson Financial Group LLC increased its position in Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after purchasing an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in Evolus in the 4th quarter valued at about $34,000. Wexford Capital LP acquired a new stake in shares of Evolus during the 3rd quarter worth about $37,000. Tower Research Capital LLC TRC boosted its stake in shares of Evolus by 340.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after purchasing an additional 5,691 shares during the last quarter. Finally, Aquatic Capital Management LLC acquired a new stake in shares of Evolus during the 3rd quarter worth about $48,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Trading Down 2.7%

Shares of NASDAQ:EOLS opened at $6.94 on Wednesday. The stock’s 50-day moving average price is $6.32 and its two-hundred day moving average price is $5.55. Evolus, Inc. has a 12-month low of $3.86 and a 12-month high of $10.20. The firm has a market cap of $457.07 million, a price-to-earnings ratio of -10.36 and a beta of 1.34.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings data on Monday, May 4th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). The firm had revenue of $73.14 million for the quarter, compared to the consensus estimate of $72.52 million. During the same period in the prior year, the company posted ($0.30) earnings per share. As a group, research analysts forecast that Evolus, Inc. will post -0.38 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on EOLS shares. BTIG Research reissued a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research report on Wednesday, June 17th. Wall Street Zen lowered shares of Evolus from a “buy” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.